ClinicalTrials.gg

Program

TQB2101

A development code. Also written as “TQB2101 for Injection” and “TQB2101 for injection”.

In Sino Biopharmaceutical's pipeline, ROR1 ADC. Its studies are mostly in Breast Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 1, since Apr 17, 20252 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical22 open or runningphase 1since Apr 17, 2025Apr 17, 2025none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2101, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2025First study: phase 1 study in Breast NeoplasmsFirst studyNCT06948539 · 66 planned · China
  2. Jul 31, 2025Phase 1 study in Advanced Hematologic MalignanciesNCT07113925 · 114 planned · China

TargetBeta

“ROR1 ADC”the company's pipeline, read by Claude · source

Other programs on ROR1

ProgramCompanyFurthest phaseStudies
zilovertamab vedotinMerckphase 310
Anti-ROR1/Anti-CD3 Bispecific Antibody EMB-07ruleshanghai-epimab-biotherapeutics-co-ltdphase 22
Anti-ROR1 Antibody-drug Conjugate IM-1021ruleImmunomephase 11
Anti-B7-H3/Anti-ROR1-Exatecan Bispecific Antibody-drug Conjugate NEOK001ruleneok-bio-incphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07113925Advanced Hematologic Malignancies · China1RecruitingDec 2025114
NCT06948539Breast Neoplasms · China1Not yet recruitingOct 202666

How it is read

Names in the registry

  • “TQB2101 for Injection”, 1 entry
  • “TQB2101 for injection”, 1 entry

Codes read as this program: TQB2101.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.